Malignant transformation of plexiform neurofibroma to MPNST while on MEK inhibitor

Samir Fasih†, Suganth Suppiyah†, Jane Barron, Carolina Barnett-Tapia, Roger Avery, Brendan Dickson, Peter Ferguson, Carol Swallow, Gelareh Zadeh‡, and Abha A. Gupta

Division of Medical Oncology, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada (S.F., A.A.G.); Division of Neurosurgery, University Health Network, University of Toronto, Toronto, Ontario, Canada (S.S., C.B.-T., G.Z.); Discipline of Laboratory Medicine, Memorial University of Newfoundland, St. John’s, Newfoundland and Labrador, Canada (J.B.); Department of Surgery, Memorial University of Newfoundland, St. John’s, Newfoundland and Labrador, Canada (R.A.); Department of Pathology, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada (P.F.); Department of General Surgery, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada (C.S.)

†These authors are the co-first authors.

Corresponding Author: Abha A. Gupta, MD, MSc, Division of Medical Oncology, Princess Margaret Cancer Center, University of Toronto, 610 University Ave., Toronto, ON, Canada (Abha.gupta@uhn.ca).

Neurofibromatosis type 1 (NF1) is a neurocutaneous tumor predisposition syndrome resulting in the development of multiple peripheral nerve sheath tumors, or, plexiform neurofibromas (PN), some of which can transform into high-grade sarcomas, called malignant peripheral nerve sheath tumors (MPNST).1 NF1-associated MPNST are highly aggressive sarcomas with a 5-year survival ranging from 20% to 50%, as these tumors have high rates of local recurrence and distant metastasis.2 Oral selective mitogen-activated protein kinase (MAPK) kinase (MEK) inhibitors have shown impressive clinical activity in children and adolescents with PN with durable and significant decrease in tumor volume.3–6 Exploration of the safety and efficacy of MEK inhibitors in adults is also emerging.7 We report 2 young adults with NF1 who developed MPNST within a few months of starting MEK inhibitors.

A 33-year-old male with NF1 was being followed for a cervical spine PN since age 26. He had previously undergone surgery (2012) and radiation (2016) for this lesion, but then due to recurrent pain, repeat imaging and biopsy were done 02/2019, confirming PN. Trametinib (2 mg once daily) was started 04/2019 with significant improvement in limb weakness. He continued drug until 30/6/2019, at which time he developed cervical cord compression leading to respiratory compromise (Figure 1). Repeat MRI showed complete cord effacement and filling the canal with tumor; patient died of respiratory failure on 2/7/2019, 3 months after starting Trametinib. Partial autopsy confirmed malignant transformation to MPNST.

The second patient was a 25-year-old female with NF1, who had numerous stable PN. One of the intrathoracic lesions caused chronic dysphagia and pain for which she started Trametinib 10/2018 (2 mg once daily). In 06/2019 she had increasing pain and size of the left lower abdominal wall and right buttock lesions. MRI showed marked interval enlargement of both lesions. Trametinib was stopped on 25/6/2019; both lesions were resected and demonstrated high-grade MPNST. Patient developed pulmonary metastases 7/2019 and died from disease 12/2019.

Chromosomal copy number variation profiles generated from raw methylation data demonstrated that both cases had numerous chromosomal gains and losses, reminiscent of chromothripsis. Notably, the NF1 gene locus on chromosome 17q and CDKN2A/B locus on chromosome 9p was lost in both samples, consistent with other NF1-associated MPNSTs. In addition, unsupervised clustering with t-distributed stochastic neighbor embedding (t-SNE) of the top 10,000 most variably methylated probes demonstrate that both cases share a similar methylation signature to normal NF1-associated MPNSTs.

We have demonstrated 2 adults undergoing transformation of their PN into MPNST despite being on MEK-inhibitor therapy. The impact of MEK inhibitors for young patients has been insurmountable, accounting for the FDA approval for selumetinib for the indication of PN in children and adolescents with NF1. The 2 cases we report herein were of age 33 and 25 years, and fall within the median age for MPNST.

© The Author(s) 2021. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
transformation. Both had begun drug within 6–8 months of presenting with MPNST, with demonstration of relative PN stability prior to starting drug. Starting the MEK inhibitor did not prevent malignant transformation.

With the death of these 2 young adult patients, we suggest that MEK inhibitors should only be used in adult NF1 patients who have close radiographic and clinical surveillance of all PN lesions. Further analysis is required to understand the impact of MEK inhibition on malignant transformation of PN in adults with NF1.

**Funding**
None declared.

**Conflict of interest statement.** None declared.

**Authorship Statement.** Manuscript preparation—all; laboratory analysis—S.S., G.Z.

**References**

1. Hirbe AC, Gutmann DH. Neurofibromatosis type 1: a multidisciplinary approach to care. *Lancet Neurol.* 2014;13(8):834–843.
2. Watson KL, Al Sanna GA, Kivlin CM, et al. Patterns of recurrence and survival in sporadic, neurofibromatosis Type 1-associated, and radiation-associated malignant peripheral nerve sheath tumors. *J Neurosurg.* 2017;126(1):319–329.
3. Widemann BC, Babovic-Vuksanovic D, Dombi E, et al. Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas. *Pediatr Blood Cancer.* 2014;61(9):1598–1602.
4. Dombi E, Baldwin A, Marcus LJ, et al. Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas. *N Engl J Med.* 2016;375(26):2550–2560.
5. Gross AM, Wolters PL, Dombi E, et al. Selumetinib in children with inoperable plexiform neurofibromas. *N Engl J Med.* 2020;382(15):1430–1442.
6. Gross AM, Wolters P, Baldwin A, et al. SPRINT: phase II study of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886) in children with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN). *J Clin Oncol.* 2018;36(suppl):10503–10503.
7. Coyne G, Gross AM, Dombi E, et al. Phase II trial of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886 Hydrogen Sulfate) in adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN). *J Clin Oncol.* 2020;38(suppl):3612–3612.